Valneva SE (VALN) Common Equity (2019 - 2026)
Valneva SE (VALN) posted Common Equity of $89.8 million for Q1 2026, down 27.34% sequentially from $123.6 million in Q4 2025, and down 51.29% YoY from $184.3 million in Q1 2025.
Analysis
Valneva SE (VALN) Common Equity (2019 - 2026) Analysis & Trends
Valneva SE has reported Common Equity for 8 years, with the latest figure at $89.8 million in Q1 2026.
- Quarterly Common Equity fell 51.29% year-over-year to $89.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.8 million (down 51.29% YoY) and the FY2025 annual result came in at $123.6 million, down 37.0% from the prior year.
- Common Equity fell to $89.8 million in Q1 2026 per VALN's latest filing, from $123.6 million in the prior quarter.
- Over five years, Common Equity peaked at $238.8 million in Q3 2024 and troughed at $17.7 million in Q3 2022.
- A 5-year average of $154.0 million and a median of $179.1 million in 2024 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 1141.77% in 2022, down 95.42% in 2022.
- Over 5 years, Common Equity stood at $224.2 million in 2022, then tumbled by 38.47% to $138.0 million in 2023, then soared by 40.37% to $193.7 million in 2024, then tumbled by 36.19% to $123.6 million in 2025, then declined by 27.34% to $89.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $89.8 million, $123.6 million, and $175.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.42 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 6.76 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.61 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.17 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.79 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | 94.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 94.29 Mn |
| Mar 31, 2026 | 89.80 Mn |
| Dec 31, 2025 | 123.58 Mn |
| Sep 30, 2025 | 175.92 Mn |
| Jun 30, 2025 | 211.03 Mn |
| Mar 31, 2025 | 184.35 Mn |
| Dec 31, 2024 | 193.69 Mn |
| Sep 30, 2024 | 238.83 Mn |
| Jun 30, 2024 | 179.06 Mn |
| Mar 31, 2024 | 205.57 Mn |
| Dec 31, 2023 | 137.99 Mn |
| Sep 30, 2023 | 646.63 Mn |
| Jun 30, 2023 | 207.67 Mn |
| Mar 31, 2023 | 219.80 Mn |
| Dec 31, 2022 | 606.07 Mn |
| Sep 30, 2022 | 17.75 Mn |
| Jun 30, 2022 | 18.78 Mn |
| Mar 31, 2022 | 166.56 Mn |
| Dec 31, 2021 | 18.06 Mn |
| Jun 30, 2021 | 92.81 Mn |